摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride | 56715-44-7

中文名称
——
中文别名
——
英文名称
O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride
英文别名
——
O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride化学式
CAS
56715-44-7
化学式
C6H8N2O*ClH
mdl
——
分子量
160.603
InChiKey
ASEXCDTZEMCCTB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.89
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    48.1
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride 、 ((2R,3S)-3-acetoxy-6-(((3S,8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate 在 吡啶 作用下, 反应 3.0h, 以60%的产率得到((2R,3S)-3-acetoxy-6-((10R,13S,17S)-10,13-dimethyl-17-((E)-1-(pyridin-3-ylmethoxyimino)ethyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate
    参考文献:
    名称:
    Glucal-conjugated sterols as novel vascular leakage blocker: Structure–activity relationship focusing on the C17-side chain
    摘要:
    A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C-17-side chain was also established. The sterol analogs linked with the rigid C-17-side chain side chains exhibited potent cell survival activities. In particular, analog 211, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model. (C) 2014 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2014.01.027
  • 作为产物:
    描述:
    N-pyridin-3-ylmethoxy-phthalimide一水合肼盐酸 作用下, 以 二氯甲烷乙醚 为溶剂, 反应 3.0h, 以98%的产率得到O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride
    参考文献:
    名称:
    Psoromic Acid 是一种选择性共价 Rab-异戊二烯化抑制剂,靶向自抑制 RabGGTase
    摘要:
    香叶基香叶基异戊二烯与 Rab GTP 酶(细胞内囊泡运输的关键组织者)的翻译后附着对其功能至关重要。Rab 香叶基香叶基转移酶 (RabGGTase) 负责 Rab 蛋白的异戊二烯化。最近,人们提出 RabGGTase 抑制剂是治疗癌症和骨质疏松症的潜在疗法。然而,RabGGTase 选择性抑制剂的开发因其与其他蛋白质异戊二烯基转移酶的结构和功能相似性而变得复杂。在此,我们报告鉴定了天然产物银屑病酸 (PA),其有效且选择性地抑制 RabGGTase,IC(50) 为 1.3 μM。构效关系分析表明了一个最小结构,涉及地苯丙酮核心与 3-羟基和 4-醛基序,用于与 RabGGTase 结合。RabGGTase:PA 复合物的晶体结构分析表明,PA 与 RabGGTase 的类异戊二烯结合位点形成大量疏水相互作用,并且它共价连接到 α 亚基的 N 末端。我们发现,与其他蛋白质异戊二烯转移酶相比,RabGGTase
    DOI:
    10.1021/ja211305j
点击查看最新优质反应信息

文献信息

  • [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2003101956A1
    公开(公告)日:2003-12-11
    There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.
    提供了一种组合产品,包括:(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物(或其衍生物)或药用可接受的衍生物;以及(1)WO 01/28992中权利要求1定义的化合物或(2)WO 01/28992中权利要求34的化合物或(3)化合物A或B或C或D(或药用可接受的盐)用于治疗心律不齐或其凝血控制的并发症。
  • Psoromic Acid is a Selective and Covalent Rab-Prenylation Inhibitor Targeting Autoinhibited RabGGTase
    作者:Céline Deraeve、Zhong Guo、Robin S. Bon、Wulf Blankenfeldt、Raffaella DiLucrezia、Alexander Wolf、Sascha Menninger、E. Anouk Stigter、Stefan Wetzel、Axel Choidas、Kirill Alexandrov、Herbert Waldmann、Roger S. Goody、Yao-Wen Wu
    DOI:10.1021/ja211305j
    日期:2012.5.2
    vesicular transport, is essential for their function. Rab geranylgeranyl transferase (RabGGTase) is responsible for prenylation of Rab proteins. Recently, RabGGTase inhibitors have been proposed to be potential therapeutics for treatment of cancer and osteoporosis. However, the development of RabGGTase selective inhibitors is complicated by its structural and functional similarity to other protein prenyltransferases
    香叶基香叶基异戊二烯与 Rab GTP 酶(细胞内囊泡运输的关键组织者)的翻译后附着对其功能至关重要。Rab 香叶基香叶基转移酶 (RabGGTase) 负责 Rab 蛋白的异戊二烯化。最近,人们提出 RabGGTase 抑制剂是治疗癌症和骨质疏松症的潜在疗法。然而,RabGGTase 选择性抑制剂的开发因其与其他蛋白质异戊二烯基转移酶的结构和功能相似性而变得复杂。在此,我们报告鉴定了天然产物银屑病酸 (PA),其有效且选择性地抑制 RabGGTase,IC(50) 为 1.3 μM。构效关系分析表明了一个最小结构,涉及地苯丙酮核心与 3-羟基和 4-醛基序,用于与 RabGGTase 结合。RabGGTase:PA 复合物的晶体结构分析表明,PA 与 RabGGTase 的类异戊二烯结合位点形成大量疏水相互作用,并且它共价连接到 α 亚基的 N 末端。我们发现,与其他蛋白质异戊二烯转移酶相比,RabGGTase
  • NOVEL VASCULAR LEAKAGEAGE INHIBITOR
    申请人:Industry-Academic Cooperation Foundation, Yonsei University
    公开号:US20140378399A1
    公开(公告)日:2014-12-25
    The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.
    本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡,抑制由VEGF诱导的肌动蛋白应激纤维的形成,并增强皮质肌动蛋白环结构,从而抑制血管渗漏。因此,本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的,因此具有明显优越的商业合成可行性。
  • WO2008/8398
    申请人:——
    公开号:——
    公开(公告)日:——
  • Synthesis and Fungicidal Activity of Macrolactams and Macrolactones with an Oxime Ether Side Chain
    作者:Jia-Xing Huang、Yue-Mei Jia、Xiao-Mei Liang、Wei-Juan Zhu、Jian-Jun Zhang、Yan-Hong Dong、Hui-Zu Yuan、Shu-Hua Qi、Jin-Ping Wu、Fu-Heng Chen、Dao-Quan Wang
    DOI:10.1021/jf072733+
    日期:2007.12.1
    Three series of novel macrolactams and macrolactones - 12-alkoxyimino-tetradecanlactam, 12-alkoxyiminopentadecanlactam, and 12-alkoxyiminodecanlactone derivatives (7A, 7B, and 7C) - were synthesized from corresponding 12-oxomacrolactams and 12-oxomacrolactone. Their structures were confirmed by H-1 NMR and elemental analysis. The Z and E isomers of 7A and 7B were separated, and their configurations were determined by H-1 NMR. These compounds showed fair to excellent fungicidal activities against Rhizoctonia solani Kuhn. It is interesting that the Z and E isomers of most of the compounds have quite different fungicidal activities. The fact that the compounds have a gradual increase of fungicidal activity in the order of 7A, 7C, and 7B indicated that the macrocyclic derivatives with a hydrogen-bonding acceptor (=N-O-) and a hydrogen-bonding donor (-CONH-) on the ring, and a three methylenes distance (CH2CH2CH2) between these two functional groups, exhibited the best fungicidal activity. The bioassay also showed that 7B not only has good fungicidal activity but also may have a broad spectrum of fungicidal activities.
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-